Oryzon Genomics S.A. (0RDB)
London Exchange · UK · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 2.500 |
|---|---|
| 52-week range | 2.500 – 3.495 |
| Return, 1 month / 3 months | −10.2% / −16.4% |
| Return, 1 year / 3 years | – / – |
| Trend | Below its 200-day average |
| RSI (14) | 33 |
| Volatility (1 year) | 32.6% |
| Worst drawdown (1 year) | -27.0% |
| Average daily value traded | 0.00M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Oryzon Genomics is a clinical-stage biopharmaceutical company based in Spain that works on epigenetics-based medicines. It develops small-molecule drugs that target epigenetic enzymes, with programmes in oncology and in central nervous system conditions such as neurodegenerative disease. Its work spans drug discovery and clinical development, and it partners with research organisations and pharmaceutical companies to advance its candidates through trials. The company's activities centre on laboratory research and patient studies rather than marketed products.
On this site Oryzon Genomics S.A. appears as a stock on the London Exchange (UK), code 0RDB, with prices in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Oryzon Genomics S.A. (0RDB) trades on the London Exchange in UK. It last closed at EUR 2.500 on 23 October 2026.
Its price-based Market X-Ray is 31 out of 100 (a weak price profile), ranking 3,048 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 28 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -14.2% | ||
| From 52-week high | -27.0% | ||
| Momentum | 23 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -16.4% | ||
| 6-month return | -11.9% | ||
| 12-month return, skipping the last month | – | ||
| Stability (higher is calmer) | 56 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 32.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -27.0% | ||
| Liquidity | 7 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.00M EUR | ||
| Zero-volume days | 6.7% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −2.0% |
|---|---|
| 1 month | −10.2% |
| 3 months | −16.4% |
| 6 months | −11.9% |
| 1 year | – |
| 3 years | – |
| 5 years | – |
Signals
| 50-day / 200-day average | 2.739 / 2.915 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.051 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.